| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Departments of Neurological Surgery [B. Bad., J. M. S., A. R. H., S. P., B. Bar., S. L., D. K. R., J. V.] and Radiology [T. R. P.], University of Wisconsin School of Medicine, Madison, Wisconsin 53792
Purpose: Cerebral edema is responsible for significant morbidity and mortality in patients harboring malignant gliomas. To examine the role of inflammatory cells in brain edema formation, we studied the expression cyclooxygenase (COX)-2, a key enzyme in arachidonic acid metabolism, by microglia in the C6 rodent glioma model.
Experimental Design: The expression of COX-2 in primary microglia cultures obtained from intracranial rat C6 gliomas was examined using reverse transcription-PCR, Western analysis, and prostaglandin E2 (PGE2) enzyme immunoassay. Bloodtumor barrier permeability was studied in the same tumor model using magnetic resonance imaging.
Results: In contrast to C6 glioma cells, microglia isolated from intracranial C6 tumors produced high levels of PGE2 through a COX-2-dependent pathway. To test whether the observed microglia COX-2 activity played a role in brain edema formation in gliomas, tumor-bearing rats were treated with rofecoxib, a selective COX-2 inhibitor. Rofecoxib was as effective as dexamethasone in decreasing the diffusion of contrast material into the brain parenchyma (P = 0.01, rofecoxib versus control animals), suggesting a reduction in bloodtumor barrier permeability.
Conclusions: These findings suggest that glioma-infiltrating microglia are a major source of PGE2 production through the COX-2 pathway and support the use of COX-2 inhibitors as possible alternatives to glucocorticoids in the treatment of peritumoral edema in patients with malignant brain tumors.
This article has been cited by other articles:
![]() |
E. Candelario-Jalil, S. Taheri, Y. Yang, R. Sood, M. Grossetete, E. Y. Estrada, B. L. Fiebich, and G. A. Rosenberg Cyclooxygenase Inhibition Limits Blood-Brain Barrier Disruption following Intracerebral Injection of Tumor Necrosis Factor-{alpha} in the Rat J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 488 - 498. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |